Cellular KRAS(G12C) Protein Degradation in PROTAC LC-2 Treated MIA PaCa-2 Cells by Western Blot
KRAS(G12C)
KRAS(G12C)
KRAS(G12C)
MIA PaCa-2 cells from ATCC
Western Blot
KRAS(G12C) mutant MIA PaCa-2 pancreatic cancer cells were seeded into the wells of 12-well plates. The cells were treated with reference PROTAC compound LC-2 for 24 hours. The cell lysates were subjected to Western blot analysis. The blot was probed with KRAS antibody and then re-probed with α-Tubulin antibody. The membrane was scanned by LI-COR Odyssey Fc Imaging System. The specific bands of interest were quantified by LI-COR Image Studio Lite software. KRAS(G12C) expression bar graph was plotted using the GraphPad Prism program.
LI-COR Odyssey Fc Imaging System
| Compound |
|---|
| LC-2 |
Malvern, PA, USA
More information can be found on our website Protein Degradation Assay – PROTAC Screening
Western blot for detection of KRAS(G12C) degradation in PROTAC LC-2 treated MIA PaCa-2 cells
Western blot quantification for detection of PROTAC LC-2 induced KRAS(G12C) degradation
